Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Common Equity (2017 - 2025)

Arcus Biosciences has reported Common Equity over the past 9 years, most recently at $631.0 million for Q4 2025.

  • Quarterly results put Common Equity at $631.0 million for Q4 2025, up 30.1% from a year ago — trailing twelve months through Dec 2025 was $631.0 million (up 30.1% YoY), and the annual figure for FY2025 was $631.0 million, up 30.1%.
  • Common Equity for Q4 2025 was $631.0 million at Arcus Biosciences, up from $436.0 million in the prior quarter.
  • Over the last five years, Common Equity for RCUS hit a ceiling of $842.0 million in Q4 2021 and a floor of $436.0 million in Q3 2025.
  • Median Common Equity over the past 5 years was $602.3 million (2021), compared with a mean of $612.0 million.
  • Biggest five-year swings in Common Equity: surged 372.7% in 2021 and later fell 29.68% in 2023.
  • Arcus Biosciences' Common Equity stood at $842.0 million in 2021, then fell by 21.97% to $657.0 million in 2022, then dropped by 29.68% to $462.0 million in 2023, then increased by 4.98% to $485.0 million in 2024, then skyrocketed by 30.1% to $631.0 million in 2025.
  • The last three reported values for Common Equity were $631.0 million (Q4 2025), $436.0 million (Q3 2025), and $549.0 million (Q2 2025) per Business Quant data.